Picture: BLOOMBERG / DAVID PAUL MORRIS
Overall, Altria has recorded $8.6bn in impairment charges after it took a 35% stake in Juul for $12.8bn in December 2018. Those charges brought down the value of its investment to $4.2bn as of the end of 2019, Altria said. “It’s a major black eye for the management. It’s a major strategic mistake in hindsight,” CFRA Research analyst Garrett Nelson said.
E-cigarette companies are also facing a May deadline to submit applications to the US Food and Drug Administration, proving that their products provide a net benefit to public health. If a company fails to make its case, the FDA has the power to order its products off the market.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: